Edap Tms vs Iridex
FOCL and IRIX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FOCL and IRIX compare
Iridex scores higher on the StockData Score (8 against 0 for Edap Tms), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FOCL | IRIX |
|---|---|---|
| Size and price | ||
| Market cap | – | $12.1M |
| Share price | $3.25 | $0.690 |
| Change, 1 year | 61.0% | −27.7% |
| Change, 5 years | −39.7% | −91.0% |
| Beta (5Y) | 0.51 | 0.93 |
| Employees | 289 | 93 |
| StockData Score | ||
| Total score | 0 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 2 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 0.2× |
| P/B | – | 3.3× |
| FCF yield | – | −16.5% |
| Growth | ||
| Revenue growth (TTM) | – | 3.7% |
| Revenue growth, 5Y average | – | 7.7% |
| Profitability | ||
| Gross margin | – | 35.9% |
| Operating margin | – | −5.4% |
| Net margin | – | −6.9% |
| FCF margin | – | −3.9% |
| Return on equity | – | −73.1% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | – | 1.82 |
| Altman Z-score | – | −2.50 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 41.5% | 12.4% |
| Held by insiders | 6.4% | 76.1% |
| Insider net buying, 12 months | $593K (better) | $536K |
| Short interest, % of float | – | 0.94% |
Go deeper
- FOCL stock overview
- FOCL income statement
- FOCL valuation and score
- IRIX stock overview
- IRIX income statement
- IRIX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.